Praveen Dayalu1, Kelvin L Chou. 1. University of Michigan Medical School, Department of Neurology, 1500 E. Medical Center Drive, 1914 Taubman Center, Ann Arbor, MI 48109-5316, USA. pravd@med.umich.edu
Abstract
BACKGROUND: Antipsychotic drugs have revolutionized the management of psychosis. Unfortunately, these drugs may cause a variety of distressing acute and delayed movement disorders, collectively known as 'extrapyramidal symptoms' (EPS). OBJECTIVE: This review summarizes the current knowledge of the phenomenology, epidemiology, and pathophysiology of EPS, while highlighting their prevention and management. METHODS: The review is limited to movement disorders resulting from typical and atypical antipsychotics. Recent and higher-quality evidence is emphasized. CONCLUSION: The pathophysiology of these disorders is still unclear. The use of atypical antipsychotics may have reduced EPS but has far from eliminated them. Available treatment options are often disappointing, especially for akathisia and the tardive syndromes. Future work will identify better treatments for these symptoms, as well as new antipsychotic agents that do not cause EPS.
BACKGROUND: Antipsychotic drugs have revolutionized the management of psychosis. Unfortunately, these drugs may cause a variety of distressing acute and delayed movement disorders, collectively known as 'extrapyramidal symptoms' (EPS). OBJECTIVE: This review summarizes the current knowledge of the phenomenology, epidemiology, and pathophysiology of EPS, while highlighting their prevention and management. METHODS: The review is limited to movement disorders resulting from typical and atypical antipsychotics. Recent and higher-quality evidence is emphasized. CONCLUSION: The pathophysiology of these disorders is still unclear. The use of atypical antipsychotics may have reduced EPS but has far from eliminated them. Available treatment options are often disappointing, especially for akathisia and the tardive syndromes. Future work will identify better treatments for these symptoms, as well as new antipsychotic agents that do not cause EPS.
Authors: James J Crowley; Yunjung Kim; Jin Peng Szatkiewicz; Amanda L Pratt; Corey R Quackenbush; Daniel E Adkins; Edwin van den Oord; Molly A Bogue; Hyuna Yang; Wei Wang; David W Threadgill; Fernando Pardo-Manuel de Villena; Howard L McLeod; Patrick F Sullivan Journal: Mamm Genome Date: 2011-12-30 Impact factor: 2.957
Authors: Holly M Holmes; Lillian C Min; Michael Yee; Ravi Varadhan; Jenny Basran; William Dale; Cynthia M Boyd Journal: Drugs Aging Date: 2013-09 Impact factor: 3.923
Authors: David D Kim; Alasdair M Barr; Yunsun Chung; Jessica W Y Yuen; Mahyar Etminan; Bruce C Carleton; Randall F White; William G Honer; Ric M Procyshyn Journal: CNS Drugs Date: 2018-10 Impact factor: 5.749
Authors: Mark Mohan Kaggwa; Rahel Nkola; Sarah Maria Najjuka; Felix Bongomin; Scholastic Ashaba; Mohammed A Mamun Journal: Risk Manag Healthc Policy Date: 2021-07-01